by Brandon Kelloway | May 15, 2024 | Innovation, Artificial Intelligence, Ideation, Evaluation, & Collaboration, IP Suite, IQ Ideas+, Patent Filing & Litigation
As featured on Engineering.com Navigating new inventorship guidance from the USPTO regarding generative AI. Generative AI has undoubtedly reshaped innovation landscapes, ushering in a new era of creativity and efficiency. However, with great technological...
by Brandon Kelloway | Apr 30, 2024 | Innovation, Artificial Intelligence, Ideation, Evaluation, & Collaboration, IP Suite, IQ Ideas+, Patent Filing & Litigation
Generative AI is a type of Artificial Intelligence machine learning with the primary goal of learning and analyzing patterns and structures of input information to “generate” – creating outputs of all varieties from written information and formulaic solutions to...
by Brandon Kelloway | Mar 20, 2024 | Innovation, Patent Filing & Litigation
As tech companies have invested vast amounts of money into acquiring computational resources and datasets, and hiring skilled personnel with the goal of AI development, training, and computational research, researchers in academia and the public sector have been left...
by Brandon Kelloway | Mar 12, 2024 | Innovation, Patent Filing & Litigation
According to a report by SuperData Research, the global gaming market was valued at $159.3 billion in 2020. This includes revenue from console games, PC games, mobile games, and e-sports. To put that in perspective, the music industry was valued at $19.1 billion in...
by Brandon Kelloway | Jan 29, 2024 | Innovation, IP Strategy, IP Suite, Patent Filing & Litigation
Over the last decade, the total annual patent applications submitted to the United States Patent and Trademark Office (USPTO) each year is over 600,000 applications. The fastest patent review process time is 6-12 months if fast-tracked via Track One, with the average...
by Brandon Kelloway | Dec 13, 2023 | Innovation
The impact of current inflation rates, the consolidation of organizations within the healthcare & pharmaceutical industries, and pharmaceutical price implications on U.S. government health programs such as Medicare and Medicaid have brought the Bayh-Dole Act back...